3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Ovarian Neoplasms
10
Fallopian Tube Neoplasms
10
Prostatic Neoplasms
7
Carcinoma, Ovarian Epithelial
6
Endometrial Neoplasms
5
Breast Neoplasms
5
Recurrence
3
Pancreatic Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Neoplasm Metastasis
2
Metastatic Castration Resistant Prostate Cancer
2
Lung Neoplasms
2
Carcinoma, Transitional Cell
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostate Cancer Metastatic
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related
1
Interventions
Pemetrexed
15
Cisplatin
13
pembrolizumab
6
Platinum
4
1,2-diaminocyclohexaneplatinum II citrate
4
cediranib
3
Radiotherapy
3
Gemcitabine
3
Carboplatin
3
amatuximab
2
Radiotherapy, Intensity-Modulated
2
Radiation
2
Everolimus
2
Drug Therapy
2
Cyclophosphamide
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tremelimumab
1
sodium thiosulfate
1
sargramostim
1
nintedanib
1
napabucasin
1
methoxyamine
1
liposomal doxorubicin
1
incomplete Freund's adjuvant
1
fresolimumab
1
durvalumab
1
defactinib
1
cixutumumab
1
bintrafusp alfa protein, human
1
bemcentinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Mesothelioma, Malignant
×
rucaparib
×
Clear all
No trials found.